JPRN-UMIN000005707已完成2 期
Phase II study of R-CHOP and R-high-dose MTX therapy for untreated intravascular large B-cell lymphoma (PRIMEUR-IVL) - Phase II study of R-CHOP and R-high-dose MTX therapy for IVLBC
IVL study group in Japan0 个研究点目标入组 38 人开始时间: 2011年6月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
With a median follow-up of 3.9 years (IQR 2.5 to 5.5), 2-year progression-free survival was 76% (95% CI 58 to 87). 2-year overall survival was 92% (95% CI 77 to 97). The cumulative incidence of secondary CNS recurrence at 2 years was 3% (95% CI 0.2 to 12).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. De novo DLBCL 2. CNS involvement on CT and/or MRI, or CSF examination 3. Glaucoma requiring treatment 4. Diabetes mellitus requiring insulin treatment 5. Hypertension 6. Positive on HBsAg. HBV-DNA positive if HBsAb and/or HBcAb are positive 7. Positive on HCV Ab 8. Positive on HIV Ab 9. Interstitial pneumonitis, pulmonary fibrosis, and sever pulmonary emphysema 10. Sever infection 11. Active cancers 12. Past history of leukemia, lymphoma and myelodysplastic syndrome 13. Having treatment with major tranquilizer, antidepressant, and antimanic 14. Psychiatric diseases
研究者
相似试验
已完成
2 期
A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphomaaggressive lymphomaJPRN-UMIN000048724the Hematological Malignancy Clinical Study Group30
进行中（未招募）
2 期
Phase II study of R-CHOP and R-high-dose MTX therapy for IVLBCJPRN-jRCTs041180165Yamaguchi Motoko37
已完成
2 期
Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000008145Kyoto Prefectural University of Medicine/K-LSG33
已完成
2 期
A phase II study of preoperative DOS for cStage III gastric cancerGastric cancerJPRN-jRCTs051180086Kurokawa Yukinori50
已完成
不适用
A phase II study of S-1 therapy for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxane (OGSG1404)Esophageal carcinomaJPRN-UMIN000016830Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)17